Oak Ridge Investments LLC purchased a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 174,572 shares of the specialty pharmaceutical company’s stock, valued at approximately $6,983,000. Oak Ridge Investments LLC owned 0.34% of Supernus Pharmaceuticals as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of SUPN. Meeder Asset Management Inc. lifted its stake in shares of Supernus Pharmaceuticals by 3,455.2% in the 2nd quarter. Meeder Asset Management Inc. now owns 2,382 shares of the specialty pharmaceutical company’s stock valued at $103,000 after purchasing an additional 2,315 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Supernus Pharmaceuticals by 278.2% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock valued at $130,000 after buying an additional 2,220 shares in the last quarter. Riverhead Capital Management LLC increased its position in shares of Supernus Pharmaceuticals by 91.4% in the 2nd quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 1,462 shares in the last quarter. Advisor Group Inc. increased its holdings in Supernus Pharmaceuticals by 13.7% during the 2nd quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock worth $145,000 after purchasing an additional 410 shares in the last quarter. Finally, Victory Capital Management Inc. increased its holdings in Supernus Pharmaceuticals by 17.7% during the 2nd quarter. Victory Capital Management Inc. now owns 3,441 shares of the specialty pharmaceutical company’s stock worth $148,000 after purchasing an additional 517 shares in the last quarter. 96.45% of the stock is currently owned by institutional investors.

Shares of Supernus Pharmaceuticals, Inc. (SUPN) traded up $0.10 on Friday, hitting $38.00. 459,563 shares of the stock traded hands, compared to its average volume of 619,784. Supernus Pharmaceuticals, Inc. has a 12 month low of $20.55 and a 12 month high of $50.04. The company has a market capitalization of $1,940.00, a PE ratio of 35.09, a PEG ratio of 1.57 and a beta of 1.30.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The company had revenue of $80.40 million for the quarter, compared to analysts’ expectations of $78.74 million. The firm’s quarterly revenue was up 41.5% compared to the same quarter last year. research analysts predict that Supernus Pharmaceuticals, Inc. will post 1.07 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “174,572 Shares in Supernus Pharmaceuticals, Inc. (SUPN) Purchased by Oak Ridge Investments LLC” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/18/174572-shares-in-supernus-pharmaceuticals-inc-supn-purchased-by-oak-ridge-investments-llc.html.

A number of research firms have issued reports on SUPN. Jefferies Group LLC reiterated a “buy” rating and set a $51.00 target price on shares of Supernus Pharmaceuticals in a report on Friday, August 4th. Piper Jaffray Companies reiterated a “hold” rating and set a $41.00 target price on shares of Supernus Pharmaceuticals in a report on Tuesday, September 26th. BidaskClub upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 17th. Cantor Fitzgerald restated a “buy” rating and issued a $49.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, September 27th. Finally, B. Riley restated a “buy” rating and issued a $50.00 price objective (down previously from $53.00) on shares of Supernus Pharmaceuticals in a report on Monday, November 6th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $49.60.

In related news, insider Stefan K.F. Schwabe sold 95,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $46.59, for a total value of $4,426,050.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Padmanabh P. Bhatt sold 5,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $49.86, for a total transaction of $249,300.00. Following the completion of the transaction, the senior vice president now directly owns 12,500 shares in the company, valued at $623,250. The disclosure for this sale can be found here. Insiders have sold 150,000 shares of company stock worth $7,055,350 over the last ninety days. Insiders own 6.70% of the company’s stock.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Stock Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.